Key result
Adjuvant nondiuretic pharmacotherapies, particularly tolvaptan and serelaxin, may improve decongestion in acute heart failure, based on a systematic review of 23 randomized controlled trials.
Why the study?
Diuretic resistance during acute heart failure poses a substantial challenge, and evidence is lacking on the optimal strategies to tackle this problem.
Do adjuvant nondiuretic pharmacological treatments improve congestion relief in patients hospitalized with acute heart failure?
Comparison
Adjuvant pharmacological nondiuretic-based regimens for congestion management
Design
Systematic review of randomised controlled trials
Authors
Loading...
Tolvaptan and serelaxin show promise for decongestion in AHF; leaves open need for standardized RCTs before changing practice.
Systematic Review
Do adjuvant nondiuretic pharmacological treatments improve congestion relief in patients hospitalized with acute heart failure?
Tolvaptan and serelaxin may serve as promising adjuvant therapies for decongestion in acute heart failure, but future trials require standardized diuretic protocols and dyspnea measurements.
Emara et al. (2022) conducted a systematic review in Acute Heart Failure. Pharmacological nondiuretic-based regimens (e.g., tolvaptan, serelaxin) was evaluated on Dyspnea relief and decongestion enhancement. Adjuvant nondiuretic pharmacotherapies, particularly tolvaptan and serelaxin, may improve decongestion in acute heart failure, based on a systematic review of 23 randomized controlled trials.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: